NEW DELHI : The Indian Council for Medical Research (ICMR) said Thursday that it has developed highly purified ‘antisera’ for the prevention and treatment of the novel coronavirus pandemic. “ICMR and Biological E. Limited, Hyderabad have developed highly purified (animal-raised) antisera for the prophylaxis and treatment of COVID-19,” reads a statement from ICMR.
Biological E. Limited is one of the listed entities that has been permitted to manufacture the vaccines for limited use by the Central Drug Control Organization (CDSCO). Other entities of this type are: Serum Institute of India, Cadila Healthcare, Bharat Biotech International Limited, Biological E Limited, Reliance Life Sciences Pvt Limited, Aurbindo Pharma Limited and Gennova Biopharmaceuticals Limited.
The lead medical body also stated that these measures have previously been used in medical science to control many viral and bacterial infections, such as rabies, hepatitis B, vaccinia virus, tetanus, botulism, and diphtheria.
“Although plasma recovered from patients experiencing COVID-19 could serve a similar purpose, the antibody profile, efficacy, and concentration vary from patient to patient and therefore make it an unreliable clinical tool for management. of the patient, “said the ICMR.
In addition, the ICMR added: “The standardization that can be achieved through the equine serum-based treatment modality stands out as another notable public health initiative endorsed by the ICMR in the time of COVID 19.”
Meanwhile, India today recorded 86,821 new coronavirus cases and 1,181 deaths in a 24-hour span, bringing the overall count to 63,12,584.
Of the total Covid-19 cases, 9,40,705 are currently active, 52,73,201 have been discharged, while 98,678 lost the battle against the deadly virus.
While India’s recovery rate remains at a very high level of 83.53%, the mortality rate has dropped to 1.56%, as confirmed by recent data from the Ministry of Health and Family Welfare.
However, Maharashtra remains the worst affected with around 13,84,446 Covid cases, including 36,662 deaths. Maharashtra is followed by Andhra Pradesh, Tamil Nadu, Karnataka, Uttar Pradesh and Delhi.
According to the latest ICMR data, the country conducted 14,23,052 sample tests in a single day on September 30, bringing the total number of samples analyzed so far to 7,56,19,781.
.
